As SME IPOs gain traction among investors, regulators are moving to formalise the market with stricter controls. The NSE recently imposed a cap on SME issue listing prices at 90%, independent of grey market trends. This impacted Nephro Care, which despite a 300% pre-listing GMP, debuted at only a 90% premium due to the exchange’s price cap.
Mark Matthews sees risk of 20% market correction in 2025, warns valuations are high
We have not reduced our own risk in our portfolios. But we are suspecting that at some point this year, there will be a reason
January 10, 2025